| Literature DB >> 26075602 |
Yu-Sheng Lin1, Tien-Hsing Chen2, Sheng-Ping Hung3, Dong Yi Chen2, Chun-Tai Mao4, Ming-Lung Tsai2, Shih-Tai Chang5, Chun-Chieh Wang2, Ming-Shien Wen2, Mien-Cheng Chen6.
Abstract
BACKGROUND: Several risk factors for pacemaker (PM) related complications have been reported. However, no study has investigated the impact of lead characteristics on pacemaker-related complications. METHODS ANDEntities:
Mesh:
Year: 2015 PMID: 26075602 PMCID: PMC4468132 DOI: 10.1371/journal.pone.0128320
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study design and flow chart of patient selection.
CIED = cardiac implantable electronic devices; ICD = implantable cardiac defibrillator; CRT = cardiac resynchronization therapy; CRTD = cardiac resynchronization therapy defibrillator; PM = pacemaker.
Patient Characteristics at Implant Stratified by Lead Fixation Method and Insulation (n = 36,104).
| Fixation method | Insulation | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Active fixation | Passive fixation | Both fixation |
| Silicone | Polyurethane | Both insulation |
|
| Number of patient | 3,766 | 29,250 | 3,088 | — | 29,453 | 3,140 | 3,511 | — |
| Gender––no. (%) | <0.001 | 0.001 | ||||||
| Male | 2,058 (54.6) | 14,871 (50.8) | 1,518 (49.2) | 15,142 (51.4) | 1,502 (47.8) | 1,803 (51.4) | ||
| Female | 1,708 (45.4) | 14,379 (49.2) | 1,570 (50.8) | 14,311 (48.6) | 1,638 (52.2) | 1,708 (48.6) | ||
| Age––yr±SD | 74.6±11.8 | 73.1±12.7 | 74.7±10.5 | <0.001 | 73.4±12.4 | 73.5±12.6 | 73.5±12.6 | 0.849 |
| Age group––no. (%) | <0.001 | 0.003 | ||||||
| < 20 yrs | 14 (0.4) | 252 (0.9) | 4 (0.1) | 229 (0.8) | 19 (0.6) | 22 (0.6) | ||
| 20~49 yrs | 130 (3.5) | 1,090 (3.7) | 77 (2.5) | 1,019 (3.5) | 130 (4.1) | 148 (4.2) | ||
| 50~59 yrs | 258 (6.9) | 2,013 (6.9) | 203 (6.6) | 2,005 (6.8) | 202 (6.4) | 267 (7.6) | ||
| 60~69 yrs | 597 (15.9) | 5,504 (18.8) | 533 (17.3) | 5,483 (18.6) | 553 (17.6) | 598 (17.0) | ||
| 70~79 yrs | 1,431 (38.0) | 11,676 (39.9) | 1,262 (40.9) | 11,769 (40.0) | 1,264 (40.3) | 1,336 (38.1) | ||
| >80 yrs | 1,336 (35.5) | 8,715 (29.8) | 1,009 (32.7) | 8,948 (30.4) | 972 (31.0) | 1,140 (32.5) | ||
| Device type––no. (%) | <0.001 | <0.001 | ||||||
| Single chamber PPM | 547 (14.5) | 21,567 (73.7) | 0 (0.0) | 19,566 (66.4) | 2,548 (81.1) | 0 (0.0) | ||
| Dual chamber PPM | 3,219 (85.5) | 7,683 (26.3) | 3,088 (100.0) | 9,887 (33.6) | 592 (18.9) | 3,511 (100.0) | ||
| Indication––no. (%) | ||||||||
| AV block | 1,462 (38.8) | 10,517 (36.0) | 986 (31.9) | <0.001 | 10,405 (35.3) | 1,158 (36.9) | 1,402 (39.9) | <0.001 |
| Congenital AV block | 1 (0.0) | 60 (0.2) | 0 (0.0) | 0.002 | 57 (0.2) | 3 (0.1) | 1 (0.0) | 0.046 |
| AF | 1,016 (27.0) | 5,842 (20.0) | 667 (21.6) | <0.001 | 6,038 (20.5) | 610 (19.4) | 877 (25.0) | <0.001 |
| Sick sinus syndrome | 1,813 (48.1) | 14,742 (50.4) | 1,726 (55.9) | <0.001 | 14,956 (50.8) | 1,620 (51.6) | 1,705 (48.6) | 0.024 |
| Comorbidity––no. (%) | ||||||||
| Diabetes | 1,235 (32.8) | 8,139 (27.8) | 947 (30.7) | <0.001 | 8,236 (28.0) | 970 (30.9) | 1,115 (31.8) | <0.001 |
| Liver cirrhosis | 103 (2.7) | 808 (2.8) | 89 (2.9) | 0.920 | 807 (2.7) | 100 (3.2) | 93 (2.6) | 0.317 |
| Obstructive lung disease | 401 (10.6) | 2,491 (8.5) | 318 (10.3) | <0.001 | 2,561 (8.7) | 309 (9.8) | 340 (9.7) | 0.022 |
| CKD | 486 (12.9) | 3,216 (11.0) | 362 (11.7) | 0.002 | 3,208 (10.9) | 414 (13.2) | 442 (12.6) | <0.001 |
| Heart failure | 547 (14.5) | 3,773 (12.9) | 376 (12.2) | 0.007 | 3,812 (12.9) | 378 (12.0) | 506 (14.4) | 0.012 |
| Hypertension | 2,701 (71.7) | 18,500 (63.2) | 2,169 (70.2) | <0.001 | 18,846 (64.0) | 2,041 (65.0) | 2,483 (70.7) | <0.001 |
| CAD | 1,412 (37.5) | 10,365 (35.4) | 1,288 (41.7) | <0.001 | 10,588 (35.9) | 1,234 (39.3) | 1,243 (35.4) | 0.001 |
| Malignant neoplasm | 530 (14.1) | 4,217 (14.4) | 459 (14.9) | 0.650 | 4,239 (14.4) | 501 (16.0) | 466 (13.3) | 0.008 |
| Medication––no. (%) | ||||||||
| Antibiotics | 3,653 (97.0) | 28,216 (96.5) | 2,952 (95.6) | 0.007 | 28,415 (96.5) | 2,993 (95.3) | 3,413 (97.2) | <0.001 |
| Warfarin | 362 (9.6) | 2,205 (7.5) | 202 (6.5) | <0.001 | 2,192 (7.4) | 243 (7.7) | 334 (9.5) | <0.001 |
| Steroid | 447 (11.9) | 3,120 (10.7) | 358 (11.6) | 0.033 | 3,065 (10.4) | 445 (14.2) | 415 (11.8) | <0.001 |
| Anti-platelet | 1,638 (43.5) | 12,161 (41.6) | 1,380 (44.7) | 0.001 | 12,075 (41.0) | 1,565 (49.8) | 1,539 (43.8) | <0.001 |
| Hospital level––no. (%) | <0.001 | <0.001 | ||||||
| Medical center | 2,347 (62.3) | 16,821 (57.5) | 1,382 (44.8) | 16,999 (57.7) | 1,524 (48.5) | 2,027 (57.7) | ||
| Metropolitan | 1,355 (36.0) | 11,667 (39.9) | 1,591 (51.5) | 11,652 (39.6) | 1,556 (49.6) | 1,405 (40.0) | ||
| Local community | 64 (1.7) | 762 (2.6) | 115 (3.7) | 802 (2.7) | 60 (1.9) | 79 (2.3) | ||
Data are presented as mean ± SD or number (percentage).
AF = atrial fibrillation; AV block = atrioventricular block; CAD = coronary artery disease; CKD = chronic kidney disease; PPM = permanent pacemaker; SD = standard deviation
a P < 0.05 for active fixation vs. passive fixation
b P < 0.05 for active fixation vs. both fixation
c P < 0.05 for passive fixation vs. both fixation
d P< 0.05 for silicon vs. polyurethane
e P < 0.05 for silicon vs. both
f P < 0.05 for polyurethane vs. both.
Lead Fixation Method and Lead Insulation vs. Early Heart Perforation Under Logistic Regression Analysis.
| Number of Event––no. (%) | Adjusted Odds Ratio and 95% CI | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Active | Passive | Both | Active | Passive | Active | ||||
|
|
|
|
|
|
|
|
|
|
|
|
| 3 (0.08) | 17 (0.06) | 2 (0.06) | 1.16 (0.19–7.23) | 0.870 | 0.66 (0.11–3.93) | 0.647 | 1.77 (0.41–7.54) | 0.441 |
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| 16 (0.05) | 2 (0.06) | 4 (0.11) | 0.54 (0.18–1.64) | 0.275 | 0.47 (0.08–2.60) | 0.384 | 1.15 (0.26–5.10) | 0.850 |
The odds ratios (OR) were adjusted for all covariates listed in Table 1.
Fig 2Kaplan–Meier estimates of the cumulative incidence of complications with different fixation types during three years of follow-up.
(A) The cumulative incidence of late heart perforation; (B) The cumulative incidence of early and late complications of pacemaker infection. The blue line indicates active fixation group, red line the passive fixation group, and the green line the both-fixation group.
Lead Fixation Method vs. Late Heart Perforation and Infection Under Cox Logistic Regression Analysis.
| Number of Event––no. (%) | Adjusted Hazard Ratio and 95% CI | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Active | Passive | Both | Active | Passive | Active | ||||
|
|
|
|
|
|
|
|
|
|
|
| Late heart perforation | 1 (0.06) | 9 (0.04) | 1 (0.04) | 1.33 (0.08–22.02) | 0.844 | 0.79 (0.10–6.26) | 0.820 | 1.69 (0.21–13.77) | 0.625 |
| Infection | 3 (0.19) | 154 (0.70) | 18 (0.73) | 0.23 (0.07–0.80) | 0.020 | 0.88 (0.54–1.44) | 0.616 | 0.26 (0.08–0.83) | 0.023 |
| Early | |||||||||
| Early infection | 3 (0.19) | 106 (0.48) | 13 (0.53) | 0.31 (0.09–1.08) | 0.066 | 0.85 (0.47–1.51) | 0.571 | 0.36 (0.11–1.14) | 0.083 |
| Late infection | 0 (0.00) | 48 (0.22) | 5 (0.20) | NA | NA | 0.99 (0.39–2.50) | 0.977 | NA | NA |
| Need of lead-extraction | |||||||||
| Need of lead extraction | 2 (0.12) | 90 (0.41) | 13 (0.53) | 0.24 (0.05–1.06) | 0.060 | 0.77 (0.43–1.39) | 0.394 | 0.31 (0.08–1.25) | 0.099 |
| Without lead extraction | 1 (0.06) | 64 (0.29) | 5 (0.20) | 0.24 (0.03–2.04) | 0.189 | 1.17 (0.47–2.93) | 0.734 | 0.20 (0.03–1.46) | 0.112 |
The hazard ratios (HR) were adjusted for all covariates listed in Table 1.
Fig 3Kaplan–Meier estimates of the cumulative incidence of complications with different insulation materials during three years follow-up.
(A) The cumulative incidence of late heart perforation; (B) The cumulative incidence of early and late complications of pacemaker infection. The blue line indicates the silicone group, the red line the polyurethane group, and the green line the both-coatings group.
Lead Insulation vs. Late Heart Perforation and Infection Under Cox Logistic Regression Analysis.
| Number of Event––no. (%) | Adjusted Hazard Ratio and 95% CI | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Silicone | Polyurethane | Combined | Silicone | Polyurethane | Silicone | ||||
|
|
|
|
|
|
|
|
|
|
|
| Late heart perforation | 9 (0.04) | 2 (0.07) | 0 (0.00) | NA | NA | NA | NA | 0.51 (0.11–2.44) | 0.399 |
| Infection | 144 (0.67) | 21 (0.68) | 10 (0.64) | 1.11 (0.58–2.13) | 0.742 | 1.15 (0.54–2.47) | 0.716 | 0.97 (0.61–1.54) | 0.889 |
| Early | |||||||||
| Early infection | 101 (0.47) | 15 (0.49) | 6 (0.38) | 1.38 (0.60–3.16) | 0.447 | 1.43 (0.55–3.72) | 0.467 | 0.97 (0.56–1.67) | 0.906 |
| Late infection | 43 (0.20) | 6 (0.20) | 4 (0.26) | 0.73 (0.26–2.06) | 0.553 | 0.76 (0.21–2.77) | 0.683 | 0.95 (0.40–2.26) | 0.915 |
| Need of lead-extraction | |||||||||
| Need of lead-extraction | 82 (0.38) | 17 (0.55) | 6 (0.38) | 1.05 (0.45–2.41) | 0.915 | 1.51 (0.59–3.88) | 0.390 | 0.69 (0.41–1.17) | 0.172 |
| Without lead-extraction | 62 (0.29) | 4 (0.13) | 4 (0.26) | 1.25 (0.45–3.47) | 0.670 | 0.61 (0.15–2.47) | 0.487 | 2.06 (0.74–5.68) | 0.165 |
The hazard ratios (OR) were adjusted for all covariates listed in Table 1.